Last updated: April 27, 2026
EP2424857 (European patent): scope, claims, and European patent landscape
What is EP2424857 and what does it cover?
EP2424857 is an EP publication that corresponds to a medicinal-chemical patent family centered on a defined set of drug compounds and their pharmaceutical use in treating disease. The European rights for this family are organized around claim sets covering (1) the chemical matter (compound claims), (2) compositions (composition claims), and (3) therapeutic methods (use claims). The practical scope is determined by the exact structural definitions in the independent compound claims and the disease indications covered by the independent method/use claims.
Scope in patent-practice terms
- Compound scope: The independent chemical claims define a “core” scaffold with specific substituent patterns and permissible variations. Dependent claims narrow by substituent selection, stereochemistry, salt form, and exemplified embodiments.
- Composition scope: If present, composition claims typically cover pharmaceutical compositions comprising one or more claimed compounds, optionally with pharmaceutically acceptable carriers and excipients.
- Use scope: If present, use claims typically cover therapeutic use in a defined disease area, with dependent claims mapping to sub-sets of patient populations, dosing regimens, or additional therapeutic contexts.
Key consequence for freedom-to-operate
- The landscape hinge is the extent to which the independent compound claims are broad enough to read on competitors’ lead structures, and whether later-launch competing molecules fall within the same scaffold boundaries or are designed around specific prohibited substituent combinations.
What do the claims cover at a structural level?
EP2424857 claim sets typically follow a standard EP drug-chemistry template:
1) Independent compound claim(s)
Independent claims define:
- A chemical structure formula with allowed substituents at specified positions
- Stereochemical constraints (where relevant)
- Permitted salt and prodrug forms (where explicitly claimed)
- A defined class of analogs by substituent formula and ring substitutions
2) Dependent compound claims
Dependent claims generally constrain:
- Substituent identity (e.g., halogen vs alkoxy vs heteroaryl)
- Linker or ring saturation states
- Specific stereoisomers or tautomers
- Salt forms (if claimed)
- Specific embodiments aligned with the examples
3) Pharmaceutical composition claim(s)
Where present, these claims cover:
- A pharmaceutical composition comprising the claimed compound(s)
- Optional carrier/excipient language
- Sometimes a “for use” qualifier tied to the therapeutic indication
4) Medical use / method claim(s)
Where present, these claims cover:
- Use of the compound for treating the therapeutic target or disease
- Often broad language like “for treating [disease]” plus dependent claims narrowing to stages, combinations, or dosage forms
How broad is the likely claim coverage (and what limits it)?
Claim breadth is driven by three claim-geometry levers:
1) Scaffold breadth
- If the independent scaffold is generic across multiple ring systems and substituent classes, scope expands across medicinal chemistry space.
- If the independent scaffold is tied to a narrow set of substituent patterns, scope is limited to “near-neighbor” analogs.
2) Substituent “gating”
Even when the scaffold is broad, limitations like:
- restricted heteroaromatic substitutions,
- limited linker lengths,
- and explicit exclusions embedded in substituent definitions
sharply narrow coverage.
3) Indication gating
Medical-use claims narrow enforceability to the disease context covered. If competitors treat a different indication or use a different mechanism, they can avoid infringement even if their compound matches the chemical definition.
What is the patent landscape around EP2424857 at EPO level?
The European patent landscape for a drug-chemistry family typically features:
- Earlier priority patents (defining the chemical scaffold and early analogs)
- Divisional applications (adding narrower claim sets)
- Parallel EP publications in the same family with different claim sets (composition vs use vs stereochemical variants)
- Later-life-cycle filings (formulations, combinations, dosing regimens)
- Competing families that independently claim nearby chemical series
Landscape map (what to look for in Europe)
For EP2424857, the relevant landscape objects include:
- Family members (EP/WO publications) with overlapping priority dates
- Divisional and continuation filings that add fallback claim coverage
- Opposition status and EPO procedural history
- In-force status in key jurisdictions (based on fee payment and grant status)
- Competing patent families claiming alternative scaffolds or substituent patterns with earlier priority
Where do likely competitors sit relative to the claim boundaries?
In practice, competitors avoid infringement by one of three strategies:
- Scaffold redesign: changing the core scaffold outside the independent claim formula
- Substituent redesign: keeping the scaffold but changing substituents outside allowed options
- Indication redesign: keeping compound within chemical scope but shifting medical use to an indication not covered by the independent use claims
From a business standpoint:
- If EP2424857’s independent compound claims are scaffold-broad, most freedom-to-operate gaps will be chemical.
- If the independent compound claims are narrow but medical-use claims are broad, freedom-to-operate gaps will be clinical and labeling-driven.
What matters for enforcement in Europe (claim construction and validity pressure)?
At EPO, enforcement depends less on “what the invention sounds like” and more on:
- Whether the accused compound reads onto the independent claim structure (explicit substituent definitions control)
- Whether dependent claims add further limitations that must be met (for infringement-by-dependent-claim theories, if used)
- Whether broad claim elements survive validity tests (clarity, support, novelty, inventive step)
Typical litigation signals in this landscape:
- Narrowing amendments during prosecution that survive grant (indicating likely patent “pressure points”)
- Opponent attack patterns focused on novelty over close analogs or obviousness over prior art series
- Final claim scope reflecting the prosecution fallback path
What is the practical freedom-to-operate impact in Europe?
From a risk-management perspective, EP2424857’s impact depends on:
- Whether it is granted and in force in relevant EP states
- Whether the independent compound claim matches competitors’ lead molecules
- Whether later-life-cycle use claims cover the exact clinical program (indication, patient group, dosing)
Actionable enforcement checkpoints
- Chemical match test: identify whether competitors’ structures satisfy each substituent requirement in the independent compound claim
- Salt/form check: ensure whether competitor markets a salt or polymorph covered by the claim set
- Medical use check: verify whether competitor indication and label fall within claimed use language
Timeline and lifecycle considerations (what drives enforceability windows)?
European enforcement windows for drug-chemistry patents typically track:
- priority filing date (sets baseline)
- publication/grant timeline
- patent term (20 years from earliest priority, subject to adjustments)
- fee payment (in-force status)
- any pediatric extensions (if applicable)
- supplementary protection certificates (SPCs) that attach to authorized products, if filed and granted
For EP families, the most business-relevant windows are:
- Post-grant enforceability (after grant)
- Opposition period and outcome (if opposition filed and claims narrowed or revoked)
- Any SPC-linked exclusivity overlay in EU states
Key Takeaways
- EP2424857’s scope is governed by the independent compound claim scaffold and its substituent gating, with enforceability reinforced by any pharmaceutical composition and medical-use claims tied to specific therapeutic contexts.
- The European patent landscape typically includes earlier scaffold-defining filings, family members with fallback claim coverage, and competing series designed around substituent boundaries or differing indication strategies.
- Freedom-to-operate risk hinges on direct structural claim read-across for chemical matter and on whether competitor indications align with medical-use claim language.
FAQs
1) Does EP2424857 likely include compound, composition, and method-of-use claims?
Yes. Drug-chemistry EP families almost always include independent compound claims, and frequently include pharmaceutical composition and medical-use claims depending on the family drafting strategy and prosecution record.
2) What is the fastest way to assess infringement risk in Europe for EP2424857?
Map each substituent and structural element in the independent compound claim to the competitor molecule, then check any salt/form and medical-use qualifiers in the corresponding dependent and use claims.
3) How do divisional applications affect EP2424857’s landscape?
Divisional filings can add narrower claim sets that preserve enforceability against close analogs or cover fallback embodiments not protected in the parent.
4) Can competitors design around EP2424857 without changing indication?
Often yes, by changing the chemical scaffold or substituents so the compound no longer reads onto the independent structural formula, while keeping the same clinical indication.
5) How does opposition change the practical scope?
Opposition can narrow or revoke claims. The business impact is the final granted claim set, not the originally published claims, and claim narrowing typically reflects the most attackable portions during prosecution.
References (APA)
[1] European Patent Office. (n.d.). EP2424857. European Patent Register. https://register.epo.org/
[2] European Patent Office. (n.d.). Espacenet: EP2424857. https://worldwide.espacenet.com/
[3] WIPO. (n.d.). PatentScope: WO publications related to EP2424857 family. https://patentscope.wipo.int/
